Neurophet, Inc.

As of June 30, 2026, Neurophet, Inc. carries a market capitalization of 132.77B, placing it among publicly traded companies globally. Its enterprise value stands at 94.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neurophet, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Neurophet, Inc. has 12.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 43.98, and the price-to-book ratio stands at 3.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 33.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 94.49B versus a market cap of 132.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Neurophet, Inc. maintains a current ratio of 21.20, meaning it holds 21.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.56, indicating elevated leverage, while an interest coverage ratio of -32.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neurophet, Inc. posted a negative return on equity (ROE) of -130.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.23, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, Neurophet, Inc. recorded an income tax benefit of -596.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -24.70B and -24.11B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Neurophet, Inc.'s stock has declined approximately 73.08% over the past 52 weeks. The 50-day moving average sits at 7,370.80, while the 200-day moving average is 15,722.85.

Over the twelve months ended June 30, 2026, Neurophet, Inc. generated 2.78B in revenue and converted that into -24.11B in net income, yielding earnings per share of -2,163.53. EBITDA reached -17.51B, while operating income came in at -18.64B.

As of June 30, 2026, Neurophet, Inc. holds 45.52B in cash and equivalents against 6.55B in total debt, resulting in a net debt position of 2.42B. Total book value stands at 34.60B, with working capital of 45.08B providing operational flexibility.

Neurophet, Inc. produced -16.74B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -633.17M in capital expenditures, free cash flow totaled -17.37B - equivalent to -1,559.02 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -670.25 and net profit margin of -866.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -45.50, meaning Neurophet, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Neurophet, Inc. has an Altman Z-Score of 2.76, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.